6.5 KiB
| title | chunk | source | category | tags | date_saved | instance |
|---|---|---|---|---|---|---|
| Blinded experiment | 2/3 | https://en.wikipedia.org/wiki/Blinded_experiment | reference | science, encyclopedia | 2026-05-05T09:49:01.984530+00:00 | kb-cron |
== Unblinding == "Unblinding" occurs in a blinded experiment when information is revealed to someone to whom it has been masked. In clinical studies, unblinding may occur unintentionally when a patient deduces their treatment group. Unblinding that occurs before the conclusion of an experiment is a source of bias. Some degree of premature unblinding is common in blinded experiments. When a blind is imperfect, its success is judged on a spectrum with no blind (or complete failure of blinding) on one end, perfect blinding on the other, and poor or good blinding between. Thus, the common view of studies as blinded or unblinded exemplifies a false dichotomy. The success of blinding is assessed by asking study participants about information that has been masked from them (e.g., whether the participant received the drug or placebo?). In a perfectly blinded experiment, the responses should be consistent with no knowledge of the masked information. However, if unblinding has occurred, the responses will indicate the degree of unblinding. Since unblinding cannot be measured directly, but must be inferred from participants' responses, its measured value will depend on the nature of the questions asked. As a result, it is not possible to objectively measure unblinding. Nonetheless, it is still possible to make informed judgments about the quality of a blinding. Poorly blinded studies rank above unblinded studies and below well-blinded studies in the hierarchy of evidence.
=== Post-study unblinding === Post-study unblinding is the release of masked data upon completion of a study. In clinical studies, post-study unblinding informs subjects of their treatment allocation. Removing a blind upon completion of a study is never mandatory, but is typically performed as a courtesy to study participants. Unblinding that occurs after the conclusion of a study is not a source of bias, because data collection and analysis are both complete at this time.
=== Premature unblinding === Premature unblinding is any unblinding that occurs before the conclusion of a study. In contrast with post-study unblinding, premature unblinding is a source of bias. A code-break procedure dictates when a subject should be unblinded prematurely. A code-break procedure should allow unblinding only in cases of emergency. Unblinding that occurs in compliance with the code-break procedure is strictly documented and reported. Premature unblinding may also occur when a participant infers, from the experimental conditions, information that has been masked from him. A common cause for unblinding is the presence of side effects (or effects) in the treatment group. In pharmacological trials, premature unblinding can be reduced with the use of an active placebo, which conceals treatment allocation by ensuring the presence of side effects in both groups. However, side effects are not the only cause of unblinding; any perceptible difference between the treatment and control groups can contribute to premature unblinding. A problem arises in assessing blinding because asking subjects to guess masked information may prompt them to infer it. Researchers speculate that this may contribute to premature unblinding. Furthermore, it has been reported that some subjects of clinical trials attempt to determine if they have received an active treatment by gathering information on social media and message boards. While researchers counsel patients not to use social media to discuss clinical trials, their accounts are not monitored. This behavior is believed to be a source of unblinding. CONSORT standards and good clinical practice guidelines recommend the reporting of all premature unblinding. In practice, unintentional unblinding is rarely reported.
=== Significance === Bias due to poor blinding tends to favor the experimental group, resulting in inflated effect size and risk of false positives. Success or failure of blinding is rarely reported or measured; it is implicitly assumed that experiments reported as "blind" are truly blind. Critics have pointed out that without assessment and reporting, there is no way to know if blinding succeeded. This shortcoming is especially concerning given that even a small error in blinding can produce a statistically significant result in the absence of any real difference between test groups when a study is sufficiently powered (i.e. statistical significance is not robust to bias). As such, many statistically significant results in randomized controlled trials may be caused by error in blinding. Some researchers have called for the mandatory assessment of blinding efficacy in clinical trials.
== Applications ==
=== In medicine === Blinding is considered essential in medicine, but is often difficult to achieve. For example, it is difficult to compare surgical and non-surgical interventions in blind trials. In some cases, sham surgery may be necessary to blind the study. A good clinical protocol ensures that blinding is as adequate as possible within ethical and practical constraints. Studies of blinded pharmacological trials across diverse domains report high rates of unblinding. Unblinding has been shown to affect both patients and clinicians. This evidence challenges the common assumption that blinding is highly effective in pharmacological trials. Unblinding has also been documented in clinical trials outside of pharmacology.
==== Pain ==== A 2018 meta-analysis found that assessment of blinding was reported in only 23 out of 408 randomized controlled trials for chronic pain (5.6%). The study concluded, based on an analysis of pooled data, that the overall quality of blinding was poor and that blinding was "not successful." Additionally, both pharmaceutical sponsorship and the presence of side effects were associated with lower rates of reporting assessment of blinding.
==== Depression ==== Studies have found evidence of extensive unblinding in antidepressant trials: at least three-quarters of patients were able to guess their treatment assignment correctly. Unblinding also occurs in clinicians. Better blinding of patients and clinicians reduces effect size. Researchers concluded that unblinding inflates the effect size in antidepressant trials. Some researchers believe that antidepressants are not effective for the treatment of depression and only outperform placebos due to systematic error. These researchers argue that antidepressants are just active placebos.